Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CTMX 
CytomX Therapeutics Inc (CTMX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: CTMX (3-star) is a STRONG-BUY. BUY since 34 days. Profits (190.00%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 52.44% | Avg. Invested days 27 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 332.42M USD | Price to earnings Ratio 4.4 | 1Y Target Price 5.5 |
Price to earnings Ratio 4.4 | 1Y Target Price 5.5 | ||
Volume (30-day avg) 8780344 | Beta 2.12 | 52 Weeks Range 0.40 - 3.10 | Updated Date 06/22/2025 |
52 Weeks Range 0.40 - 3.10 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 28.2% | Operating Margin (TTM) 44.43% |
Management Effectiveness
Return on Assets (TTM) 15.87% | Return on Equity (TTM) -5475.03% |
Valuation
Trailing PE 4.4 | Forward PE 7.02 | Enterprise Value 292978214 | Price to Sales(TTM) 2.48 |
Enterprise Value 292978214 | Price to Sales(TTM) 2.48 | ||
Enterprise Value to Revenue 1.99 | Enterprise Value to EBITDA 7.78 | Shares Outstanding 157544000 | Shares Floating 60985977 |
Shares Outstanding 157544000 | Shares Floating 60985977 | ||
Percent Insiders 0.83 | Percent Institutions 51.04 |
Analyst Ratings
Rating 4.17 | Target Price 5.5 | Buy 3 | Strong Buy 2 |
Buy 3 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CytomX Therapeutics Inc
Company Overview
History and Background
CytomX Therapeutics Inc. was founded in 2008 and is focused on developing probody therapeutics, which are antibodies that are activated specifically in the tumor microenvironment. It has evolved from early-stage research to clinical trials and partnerships with major pharmaceutical companies.
Core Business Areas
- Probody Therapeutics Development: CytomX's core business is the discovery and development of probody therapeutics. These are designed to be inactive until they reach the tumor microenvironment, reducing off-target effects and improving safety.
- Partnerships and Licensing: CytomX also generates revenue through partnerships and licensing agreements with pharmaceutical companies to co-develop and commercialize their probody therapeutics.
Leadership and Structure
The leadership team includes Sean McCarthy (Chairman and CEO). The organizational structure is typical of a biotech company, with departments focused on research, development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- CX-2029: CX-2029, a Probody drug conjugate (PDC) targeting CD71, is in clinical development. Market share data is unavailable due to its developmental stage, however the global drug conjugates market is dominated by Roche (RHHBY), Seagen (SGEN), and Immunomedics (acquired by Gilead). The market size for ADCs (antibody-drug conjugates) are expected to grow, but Probody drugs are a small segment of this.
- CX-904: CX-904, is a conditionally activated bispecific T-cell engager targeting EGFR and CD3. It is designed to activate T cells within the tumor microenvironment to kill cancer cells. Competitors include Regeneron (REGN) and Amgen (AMGN) who also are designing T-Cell engagers. There is no revenue or Market Share data associated with this product since it is in clinical trial phases.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. Focus on oncology and innovative drug delivery systems are key trends.
Positioning
CytomX is a pioneer in the probody therapeutics field, aiming to improve cancer treatment with safer and more effective therapies. Their competitive advantage lies in their probody technology platform.
Total Addressable Market (TAM)
The TAM for cancer therapies is enormous, projected to be hundreds of billions of dollars. CytomX is positioned to capture a portion of this market through its probody platform, specifically targeting tumors with specific activators.
Upturn SWOT Analysis
Strengths
- Probody technology platform
- Strategic partnerships with major pharmaceutical companies
- Focus on innovative cancer therapies
- Experienced management team
Weaknesses
- Reliance on research and development
- Clinical trial risks
- High cash burn rate
- Limited commercialized products
Opportunities
- Expansion of probody platform to other disease areas
- Further partnerships and licensing agreements
- Positive clinical trial results
- Increasing demand for targeted cancer therapies
Threats
- Competition from other cancer therapies
- Regulatory hurdles
- Failure of clinical trials
- Patent expirations
Competitors and Market Share
Key Competitors
- RHHBY
- MRK
- BMY
- LLY
- AZN
Competitive Landscape
CytomX faces competition from established pharmaceutical companies and biotech firms in the cancer therapy market. Their probody technology offers a unique approach, but they need to demonstrate clinical efficacy and safety to gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: CytomX's historical growth is characterized by progress in research and development and the establishment of partnerships.
Future Projections: Future growth depends on the success of clinical trials and the commercialization of probody therapeutics.
Recent Initiatives: Recent initiatives include advancing clinical trials for CX-2029 and CX-904, as well as securing new partnerships.
Summary
CytomX is a biotech company with a promising probody technology platform for cancer therapies. It faces significant clinical trial risks and competition from larger pharmaceutical companies. Success hinges on favorable clinical trial outcomes and strategic partnerships. While innovative, the company needs to watch out for potential regulatory hurdles and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CytomX Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2015-10-08 | Chairman & CEO Dr. Sean A. McCarthy DPHIL | ||
Sector Healthcare | Industry Biotechnology | Full time employees 119 | Website https://www.cytomx.com |
Full time employees 119 | Website https://www.cytomx.com | ||
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.